Re: 'Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes' by Nutman et al

Clin Microbiol Infect. 2020 Sep;26(9):1274. doi: 10.1016/j.cmi.2020.04.043. Epub 2020 May 8.

Author

S Karakonstantis¹

Affiliation

¹ School of Medicine, University of Crete, Heraklion, Crete, Greece. Electronic address: stamatiskarakonstantis@gmail.com.

PMID: 32389843
DOI: 10.1016/j.cmi.2020.04.043

No abstract available

Publication types

Letter
Comment

MeSH terms

Acinetobacter Infections* / drug therapy
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Carbapenems / pharmacology
Colistin*
Humans
Meropenem / pharmacology

Substances

Anti-Bacterial Agents
Carbapenems
Meropenem
Colistin